AI Science Tracker
EN

Machine learning-assisted serum Raman spectroscopy for risk stratification in men with suspected prostate cancer: a retrospective proof-of-concept study

Not stated in the abstract reviewed · 29 Oct 2026 · medicine

Discovery

Machine learning-assisted serum Raman spectroscopy for risk stratification in men with suspected prostate cancer: a retrospective proof-of-concept study

Source check: Source checked. Not independent scientific confirmation.

Finding: Supervised classifiers analyzed dried-serum Raman spectra from archived samples to distinguish prostate-cancer cases from symptomatic controls. The single-biobank proof of concept reported moderate discrimination and lacks external or prospective validation.

Technology: Supervised machine-learning classifiers of serum Raman spectra; XGBoost

Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Supervised machine-learning classifiers of serum Raman spectra; XGBoost
Test and result
Among 119 cancer cases and 60 symptomatic controls, reported AUC was about 0.77 overall and 0.78 in the PSA 4–10 ng/mL subgroup.
Limitation / still unknown
Single-biobank retrospective samples; no external or prospective validation. The authors note that contemporary pathway validation is needed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.medrxiv.org/content/10.64898/2026.10.26.26366514v1.full.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.